Prohost Biotech – Exclusive Biotech Research – A Comprehensive Resource for Biotech News

Exelixis: Health Canada approves Cabometyx in advanced renal cell carcinoma

Exelixis: Health Canada approves Cabometyx in advanced renal cell carcinoma

September 20, 2018 0

Exelixis’ (EXEL) partner Ipsen Biopharmaceuticals Canada Inc. received approval of Cabometyx®(cabozantinib) tablets from Health Canada for adults with advanced renal cell carcinoma (RCC) who have received prior vascular endothelial growth factor (VEGF) targeted therapy. Health Canada had granted Cabometyx priority review status, which resulted in the accelerated review of Ipsen’s new drug submission. Explaining the importance of Cabometyx’s additional approval, Michael M. Morrissey, Ph.D., …

Viking Therapeutics: VK2809 scores impressive results in non-alcoholic fatty liver disease

Viking Therapeutics: VK2809 scores impressive results in non-alcoholic fatty liver...

Argenx’s product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia

Argenx’s product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia

Gilead Sciences: In pursuit of cures for intractable diseases

Gilead Sciences: In pursuit of cures for intractable diseases

Amgen and AstraZeneca have in hand a very much needed Asthma drug

Amgen and AstraZeneca have in hand a very much needed...

Gilead and Galapagos have good news for patients with severely active Ankylosing Spondylitis

Gilead and Galapagos have good news for patients with severely...

RegenxBio has good news

RegenxBio has good news

PTC Therapeutics now with a wealthier pipeline

PTC Therapeutics now with a wealthier pipeline

When all the prophets are taken by surprise

When all the prophets are taken by surprise

Why Celyad’s stock gained $2.30 today

Why Celyad’s stock gained $2.30 today

Aerie’s successful new confirmatory study for Rhopressa® was a necessity

Aerie’s successful new confirmatory study for Rhopressa® was a necessity

Regeneron’s and Bluebird Bio’s collaboration is meant to create advanced immune cell therapy

Regeneron’s and Bluebird Bio’s collaboration is meant to create advanced...

A new European approval for Bristol-Myers’ immunotherapy opdivo. The future is starting now

A new European approval for Bristol-Myers’ immunotherapy opdivo. The future...

The EU CHMP Recommends Approving Alnylam’s RNAi Therapeutic, ONPATTRO™

The EU CHMP Recommends Approving Alnylam’s RNAi Therapeutic, ONPATTRO™

Novartis Pleased the Market with Its Q2 Financial Results and Pleased Us with Its Great Scientific Achievements. See Also: The Role AveXis and RegenxBio are Playing Towards the Future Success of Novartis

Novartis Pleased the Market with Its Q2 Financial Results and...

The FDA Clears Compugen’s and Bayer’s IND Application for Their Checkpoint Inhibitor Immunotherapy Product

The FDA Clears Compugen’s and Bayer’s IND Application for Their...

The FDA approved a combination of two products. Both belong to Array Biopharma

The FDA approved a combination of two products. Both belong...

Sarepta announced successful results from a preliminary trial for Duchenne Muscular Dystrophy

Sarepta announced successful results from a preliminary trial for Duchenne...

The FDA Approves Keytruda for primary Mediastinal Large B-Cell Lymphoma (PMBCL)

The FDA Approves Keytruda for primary Mediastinal Large B-Cell Lymphoma...

AstraZeneca and Genentech Checkpoint Inhibitors improve survival in two different Lung Cancers

AstraZeneca and Genentech Checkpoint Inhibitors improve survival in two different...

Today’s Highlights

A Bayer testing of Compugen’s checkpoint protein in human trial boosted our expectations for Compugen’s resurrection

A Bayer testing of Compugen’s checkpoint protein in human trial boosted our expectations for Compugen’s resurrection

September 21, 2018 0

Compugen Again On Sept 10, 2018, we posted in The Week in Review #28 news we found …

About Portola’s appointment of a new president. Read Also: Why CRISPR lost $2.90 today

About Portola’s appointment of a new president. Read Also: Why CRISPR lost $2.90 today

September 20, 2018 0

Portola Pharmaceuticals Appoints Scott Garland as President and Chief Executive Officer, Effective October 8, 2018. Portola (PTLA) appointed …

CRISPR Therapeutics’ new collaboration targeting Diabetes

CRISPR Therapeutics’ new collaboration targeting Diabetes

September 19, 2018 0

CRISPR Gene Editing Beyond Bringing Cures to disease-causing genes, CRISPR gene editing technology can change the way diseases …

AcelRx Pharmaceuticals: A small currently highlighted firm

AcelRx Pharmaceuticals: A small currently highlighted firm

September 14, 2018 0

Today, we see are observing an increased interest in AcelRx Pharmaceuticals (ACRX). The increased investors’ activity …

CRISPR gene editing firms clear investors’ confusion

CRISPR gene editing firms clear investors’ confusion

September 12, 2018 0

Playing buy and sell games with the CRISPR gene editing stocks is sometimes based on scientific …

What happened to Sangamo yesterday?

What happened to Sangamo yesterday?

September 6, 2018 0

The disease, mucopolysaccharidosis (MPS) type II, also known as the horrible Hunter syndrome is a killer …

Ionis, the FDA and the exaggerated selloff of the firm’s stock

Ionis, the FDA and the exaggerated selloff of the firm’s stock

August 30, 2018 0

A complete response letter (CRL) sent by The Division of Metabolism and Endocrinology Products of the …

About Portola

About Portola

August 27, 2018 0

Portola (PTLA) has two important approved breakthrough products and an investigational product having promising results on …

Starting the gene therapy chapter in the book of the biotech revolution

Starting the gene therapy chapter in the book of the biotech revolution

August 22, 2018 0

WE ARE LIVING AN HISTORIC BIOLOGICAL REVOLUTION. Unfortunately, the undeniably outstanding news has not yet penetrated …

Vertex has good news from Australia. Why selling solid firms stocks.

Vertex has good news from Australia. Why selling solid firms stocks.

August 21, 2018 0

Vertex Pharmaceuticals (VRTX) announced that the Pharmaceutical Benefits Advisory Committee’s (PBAC) in Australia recommendation the listing …

The Week in Review

What is looking good in the aggressive portfolio

What is looking good in the aggressive portfolio

September 10, 2018 0

PROHOST AGGRESSIVE PORTFOLIO - The aggressive portfolio hosts biotech firms with solid scientific fundamentals and prominent …

Outperforming, favorite, and undervalued biotech firms

Outperforming, favorite, and undervalued biotech firms

September 3, 2018 0

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid …

Bombarding future treatment approaches

Bombarding future treatment approaches

August 15, 2018 0

The Week in Review #27 PRIORITY TOPICS: CRISPR GENE EDITING, GENETIC ENGINEERING & ANTISENSE TECHNOLOGY The choice of these …

Stories about research, clinical trials results and an FDA ruling

Stories about research, clinical trials results and an FDA ruling

July 9, 2018 0

The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem …

Finding reasons for underperforming stocks

Finding reasons for underperforming stocks

July 2, 2018 0

The Week in Review #25 When Stocks Plummet for No Relevant Reasons Sometimes investors need to know …

Our outperforming firms and more

Our outperforming firms and more

June 25, 2018 0

The Week in Review #24 Biotech Stocks’ Performances, Products on the Move and Biotech Research Biotechnology …

Good news, bad news & comebacks. Some ASCO results too

Good news, bad news & comebacks. Some ASCO results too

June 19, 2018 0

The Week in Review #23 ASCO 2018 - Small publicly-traded oncology biotech firms, large oncology biotech …

An Approval & a Rejection. Both Considered Good News. A Small Firm is Added to the Prohost Portfolio

An Approval & a Rejection. Both Considered Good News. A Small Firm is Added to the Prohost Portfolio

May 7, 2018 0

The Week in Review #22 What Went Right or Wrong in the Biotech Sector During the …

AveXis Drug’s Data for Spinal Muscular Atrophy Highlights Gene Therapy

AveXis Drug’s Data for Spinal Muscular Atrophy Highlights Gene Therapy

April 30, 2018 0

The Week in Review #21 Part 2 THE MARKET (2) - Our remarks in the past Week …

The Biotech Revolution is Alive and Speeding

The Biotech Revolution is Alive and Speeding

April 24, 2018 0

The Week in Review #21 Part 1 THE MARKET - Like symphonic orchestras that bring to the listeners’ …

Prohost Letters

Victims of fear and misunderstanding

Victims of fear and misunderstanding

August 1, 2018 0

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical …

New stock selection and re-evaluation

New stock selection and re-evaluation

June 8, 2018 0

Prohost Letter #422 SUMMARY OF THE PAST ISSUE ARTICLE - REVISITING PROMISING FIRMS (PART1) - The …

Revisiting Biotech Companies We Highlighted

Revisiting Biotech Companies We Highlighted

May 25, 2018 0

Prohost Letter #421 PRIVATE LESSONS - Stock prices of publicly-traded biotech companies oscillate for the same …

Real Breakthroughs

Real Breakthroughs

April 17, 2018 0

Prohost Letter #420 REAL BREAKTHROUGHS - One Has Already Been Used and the Other Has Extraordinary …

The Prohost Portfolio: Updating the Stock Targets

The Prohost Portfolio: Updating the Stock Targets

March 15, 2018 0

Prohost Letter #419 RE-EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we …

Observing Queer Stories

Observing Queer Stories

March 2, 2018 0

Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an …

Private Lessons and More

Private Lessons and More

February 9, 2018 0

Prohost Letter #417 Private Lessons - These lessons are overdue and we had to do this …

The Year in Review Part 2

The Year in Review Part 2

January 10, 2018 0

Prohost Letter #416 Part 2 2017 - A YEAR OF BREAKTHROUGH TECHNOLOGIES, BREAKTHROUGH PRODUCTS, IMPROVEMENTS ON …

The Year in Review Part 1

The Year in Review Part 1

December 31, 2017 0

Prohost Letter #416 Part 1 The Year In Review - 2017 Unheard of Programs - AN …

Prohost Letter #415

Prohost Letter #415

December 3, 2017 0

Prohost Letter #415 New Promising Technologies PROTAC - A Technology That Offers a Superior Class of …